Drug giants Johnson & Johnson and Sanofi have suspended late-stage clinical trials of the experimental E.COLI vaccine after the results failed to demonstrate sufficient efficacy.
company It was announced on Thursday The vaccine showed no safety concerns, but did not meet the efficacy threshold required to continue development.
The experimental vaccine, known as Expec9V, was designed to protect against bloodstream infections and sepsis caused by E. coli bacteria, a major contributor to urinary tract infections and other serious health complications.
The trial, which began in June 2021, recruited elderly people over the age of 60 who had a recent history of urinary tract infections and otherwise had a stable health condition.
It was held on over 250 sites across five continents.
Despite rigorous testing and surveillance, the vaccine did not generate the desired immune response to move forward.
J&J has confirmed that independent reviews of the data have not discovered safety issues, and the company is currently following up with participants who have already received the vaccine.
J&J's shares were unchanged in pre-market trading on Thursday.
Sanofi, which partnered with J&J's Janssen unit in the vaccine development, revealed in its fourth quarter revenue report that it had recorded a $250 million claim related to the suspension trial.
However, the company reassured investors that the financial set-off will not affect the 2025 revenue forecast issued in January.
Sanofi's head of vaccine research and development, Jean-François Toussaint said the companies will analyze the test results to understand why the vaccine failed to achieve its intended efficacy.
“We'll share more insights once we've completed a comprehensive review of our data,” he added.
The failure of Expec9V represents a set break in the ongoing battle with E. Coli infection, which poses a significant public health risk.
Most strains of bacteria are harmless and are common in the intestines of humans and animals, but can cause severe illness.
More dangerous strains of E. coli can cause food-borne development, resulting in symptoms such as diarrhea, abdominal convulsions, and in severe cases renal failure.
One recent example of the risk posed by E. coli occurred last year when an outbreak linked to McDonald's Quarter Pounder Burger was hospitalized tired of 104 people.
Its outbreak was caused by the O157:H7 strain known to produce dangerous toxins that can cause severe complications.
The set-off in vaccine development highlights the challenges scientists face when creating effective vaccinations against bacterial infections.
Unlike viral diseases that often have a more predictable immune response, bacterial infections are more complex and require a deeper understanding of how to stimulate long-term immunity.
The cancellation of the Expec9V trial is disappointing, but experts believe that the insights gained from this study can inform future vaccine development efforts.
J&J and Sanofi said they are continuing to commit to advances in infectious disease prevention research and will continue to investigate alternative solutions to combat E. coli-related illnesses.
For now, health professionals have emphasized the importance of preventive measures such as proper food handling, hygiene and early treatment of urinary tract infections to reduce the risks associated with E. coli infections.
